Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Institut de Recherches Internationales Servier
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
Evaluation of the clinical efficacy and safety of Perindopril / Indapamide / Amlodipine fixed-dose combination in single-pill versus free dual therapy at the same dose as the single-pill combination in patients with uncontrolled essential hypertension
Not provided at time of registration and not expected to be available in the future
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (I.R.I.S)
MAJ Il y a 4 ans
Long-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg b.i.d.) on top of anti-anginal background therapy, to patients with chronic stable angina pectoris. An international, double-blind placebo controlled study
- To document the absence of retinal toxicity of ivabradine versus placebo in chronic stable angina patients after treatment cessation in the subset of patients with emergent bilateral relevant ERG ab...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3 1000 IU fixed combination) on vitamin D deficiency in the treatment of osteoporotic postmenopausal women and men. A 12 month, prospective, open labelled, one treatment group international phase III study
Efficacy of S6911 in patients with deficient vitamin D serum level
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period. An international multicentre, 3 parallel groups, randomised, double blind, placebo-controlled phase II study
Demonstrate a superiority of at least one dose of S 18986 vs. placebo on verbal episodic memory performance in patients with MCI over 12 months.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer
-To evaluate the objective response rate (ORR) of single agent lucitanib in metastatic breast cancer patients with FGFR1-amplified, FGFR1-non-amplified with 11q amplification, or FGFR1-non-amplified w...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Effects of ivabradine in patients with stable coronary artery disease without heart failure
To evaluate the effect of ivabradine on cardiovascular events in patients with coronary artery disease.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack. The PERFORM Study. An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial)
To demonstrate the superiority of S 18886 30 mg o.d. over aspirin 100 mg o.d., in reducing cerebrovascular and cardiovascular events of ischaemic origin (primary efficacy end point: composite of ischa...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Safety and efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms: A pilot phase IIa, international, multicentre, randomised, double-blind, parallel-group, controlled study
The primary objective of this pilot study is to assess the clinical and biological safety of S 33138 after 8 weeks of oral administration in schizophrenic patients with predominant positive symptoms.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Dose response study of a new treatment "gevokizumab" in patients with type 2 diabetes and diabetic kidney disease
The objective of this study is to detect the existence of an overall dose-response relationship with gevokizumab SC, on the measured glomerular filtration rate in patients with type 2 diabetes and dia...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Long-term safety of gevokizumab in the treatment of patients with chronic non-infectious uveitis, who previously well tolerated geovkizumab
The objective of this study is to evaluate long-term safety of gevokizumab in patient with chronic non-infectious uveitis who previously well tolerated the study drug and may benefit from longterm tre...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
7
8
9
10
11
12
13
14
15
16
Suivant